ResMed posts Q4 2026 results and raises dividend

ResMed Inc. reported higher sales and earnings for the quarter and fiscal year ended June 30, 2026, and announced a larger dividend.

Rhea-AI Filing Summary

ResMed Inc. reported higher sales and earnings for the quarter and fiscal year ended June 30, 2026, and announced a larger dividend. For the fourth quarter, revenue was $1,464 million, up 9% from $1,348 million. GAAP diluted EPS was $2.64 versus $2.58, while non-GAAP diluted EPS rose to $2.95 from $2.55. GAAP gross margin declined to 58.8% from 60.8%, reflecting items such as $41.9 million of Astral field safety notification expenses, but non-GAAP gross margin improved to 62.3% from 61.4%.

For fiscal 2026, revenue reached $5,653 million, a 10% increase year over year. GAAP diluted EPS was $10.43 versus $9.51, and non-GAAP diluted EPS increased to $11.17 from $9.55, as operating margin expanded to 33.4% and non-GAAP operating margin to 36.1%. Operating cash flow for the year was $1,806 million. The board declared a quarterly cash dividend of $0.66 per share, a 10% increase, with a record date of August 20, 2026 and payment on September 24, 2026; holders of CHESS Depositary Interests on the ASX will receive an equivalent amount based on the 10:1 CDI-to-share ratio.

Positive

• Non-GAAP earnings and margins expanded, with fiscal 2026 non-GAAP diluted EPS rising to $11.17 from $9.55 and non-GAAP operating margin improving to 36.1% from 34.3%.
• Top-line growth was solid, as fiscal 2026 revenue increased to $5,653 million, up 10% year over year, supported by both devices and masks across Americas and Rest of World.
• Shareholder returns increased, with the quarterly cash dividend raised 10% to $0.66 per share and substantial capital returned via $700,037 thousand of treasury stock purchases in fiscal 2026.

Negative

• Fourth-quarter cash generation softened, with operating cash flow of $455 million and free cash flow of $404 million, down 16% and 21% respectively versus the prior-year quarter.
• Quarterly GAAP profitability metrics compressed, as Q4 2026 GAAP gross margin fell to 58.8% from 60.8% and operating margin to 30.7% from 33.7%, including $41,885 thousand of Astral field safety notification expenses.

Filing Explained

The board has declared the quarterly dividend, with August 19, 2026 as the ex-dividend date; an ASX waiver permits deferring conversions between ResMed’s common-stock and CDI registers through August 20, 2026, affecting the processing of holder transfers around the record date.

8-K Event Classification

3 items: 2.02, 8.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Q4 2026 Revenue: $1,464 million FY 2026 Revenue: $5,653 million Q4 2026 non-GAAP diluted EPS: $2.95 +5 more

8 metrics

Q4 2026 Revenue $1,464 million Three months ended June 30, 2026 vs $1,348 million in 2025, 9% increase

FY 2026 Revenue $5,653 million Twelve months ended June 30, 2026, 10% year-over-year growth

Q4 2026 non-GAAP diluted EPS $2.95 Three months ended June 30, 2026, up from $2.55 in prior-year quarter

FY 2026 non-GAAP diluted EPS $11.17 Twelve months ended June 30, 2026, up from $9.55 in fiscal 2025

Quarterly dividend per share $0.66 Declared with record date August 20, 2026, a 10% increase over previous dividend

FY 2026 operating cash flow $1,806 million Cash provided by operating activities for twelve months ended June 30, 2026

Cash and cash equivalents $1,469,234 thousand Balance at June 30, 2026 on condensed consolidated balance sheet

Astral field safety notification expenses $41,885 thousand Recorded in cost of sales during the quarter ended June 30, 2026

Key Terms

CHESS Depositary Interests, free cash flow, field safety notification expenses, non-GAAP diluted earnings per share, +2 more

6 terms

CHESS Depositary Interests financial

"Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange"

CHESS depositary interests are tradable certificates used on the Australian settlement system that represent ownership of underlying foreign shares held by a custodian. They let investors buy and sell foreign-listed stocks on the local exchange as if they were domestic shares, simplifying trading, dividend collection and record-keeping, though they may involve custodian fees and can alter certain direct shareholder rights and tax treatments.

free cash flow financial

"Free cash flow (C) | | | 404 | | | | 508 | | | | (21)"

Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.

field safety notification expenses medical

"Astral field safety notification expenses (1) | | | 41,885"

non-GAAP diluted earnings per share financial

"Non-GAAP diluted earnings per share (A) | | $ | 11.17"

Non-GAAP diluted earnings per share is a company’s per-share profit figure that starts with reported net income but then removes or alters certain items (like one-time charges, stock-based pay, or other adjustments) and divides by the number of shares after accounting for things that could dilute ownership. Investors use it as a “cleaned-up” measure to judge ongoing profit on a per-share basis, but because companies choose what to adjust, it can be more subjective than the standard GAAP metric—like comparing a regular bank statement to one that omits irregular expenses to show a steadier month-to-month picture.

constant currency financial

"% Change | | | Constant Currency (A) | Revenue"

Constant currency is a way of measuring financial results that removes the effects of changes in currency exchange rates. It allows for a clearer comparison of a company's performance over time by showing what the numbers would look like if exchange rates had stayed the same. This helps investors understand whether growth comes from actual business improvements or just currency fluctuations.

treasury stock financial

"Treasury stock | | | (2,778,591 | ) | | | (2,073,292 | )"

Treasury stock is shares that a company has bought back from the public and kept in its own control rather than retiring them. Think of it like a company holding its own tickets in a drawer: those shares no longer vote or receive dividends while held, but the company can reissue or retire them later; this reduces the number of shares available to outside investors and can boost per‑share earnings and influence ownership and stock price.

Earnings Snapshot

Q4 2026 revenue: $1,464 million

Three and twelve months ended June 30, 2026

Q4 2026 revenue $1,464 million 9% year-over-year increase

FY 2026 revenue $5,653 million 10% year-over-year increase

Q4 2026 GAAP diluted EPS $2.64 2% year-over-year increase from $2.58

Q4 2026 non-GAAP diluted EPS $2.95 16% year-over-year increase from $2.55

FY 2026 GAAP diluted EPS $10.43 10% year-over-year increase from $9.51

FY 2026 non-GAAP diluted EPS $11.17 17% year-over-year increase from $9.55

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did ResMed (RMD) perform in the fourth quarter of fiscal 2026?

ResMed’s fourth-quarter revenue was $1,464 million, up 9% from $1,348 million a year earlier. GAAP diluted EPS was $2.64, and non-GAAP diluted EPS increased to $2.95 from $2.55, while non-GAAP gross margin improved to 62.3%.

What were ResMed (RMD)’s full-year fiscal 2026 results?

For fiscal 2026, ResMed reported revenue of $5,653 million, a 10% year-over-year increase. GAAP diluted EPS was $10.43 versus $9.51, and non-GAAP diluted EPS rose to $11.17 from $9.55, with operating margin improving to 33.4%.

What dividend did ResMed (RMD) declare and when will it be paid?

ResMed’s board declared a quarterly cash dividend of $0.66 per share, a 10% increase over the prior dividend. The dividend is payable on September 24, 2026, to shareholders of record on August 20, 2026, with an ex-dividend date of August 19, 2026.

How strong was ResMed (RMD)’s cash flow and balance sheet at June 30, 2026?

In fiscal 2026, ResMed generated $1,806 million of operating cash flow and $1,650 million of free cash flow. Cash and cash equivalents were $1,469,234 thousand at June 30, 2026, against total debt of $659,365 thousand (short-term plus long-term).

Did ResMed (RMD) incur any notable one-time or special expenses in Q4 2026?

Yes. ResMed recorded $41,885 thousand of Astral field safety notification expenses in cost of sales during Q4 2026. These costs affected GAAP gross margin, which declined to 58.8%, while non-GAAP adjustments exclude such field safety notification expenses.

How did different product categories and regions contribute to ResMed (RMD)’s Q4 2026 revenue?

In Q4 2026, total devices revenue was $750 million and masks and other revenue was $542 million. Americas revenue reached $853 million, up 8%, while Rest of World revenue was $439 million, up 13% versus the prior-year quarter.

What capital return activities did ResMed (RMD) undertake in fiscal 2026?

ResMed returned capital through dividends and buybacks, paying $349,662 thousand in dividends during fiscal 2026 and spending $700,037 thousand on purchases of treasury stock. It also issued $74,503 thousand of common stock, primarily related to employee equity programs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/06/2026 - 04:07 PM Accepted by SEC EDGAR 08/06/2026 - 04:05 PM Learn about SEC filing dates

RESMED INC US false 0000943819 0000943819 2026-08-06 2026-08-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Under Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 6, 2026

ResMed Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware		001-15317		98-0152841
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

9001 Spectrum Center Blvd.

San Diego, California 92123

(Address of Principal Executive Offices)

(858) 836-5000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.004 par value		RMD		NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 6, 2026, we issued the press release furnished as Exhibit 99.1. The press release describes the results of our operations for the quarter and fiscal year ended June 30, 2026.

The information furnished in this Current Report on Form 8-K under Item 2.02 and the attached exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01. Other Events.

On August 6, 2026, we announced that our board of directors declared a quarterly cash dividend of US $0.66 per share, representing an increase of 10% over the previous quarterly dividend. The dividend will have a record date of August 20, 2026, payable on September 24, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be August 19, 2026, for common stockholders and for CDI holders. Resmed has received a waiver from the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from August 19, 2026, through August 20, 2026, inclusive.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibits:		Description of Document
99.1		Press Release dated August 6, 2026, regarding results of operations
104		Cover Page Interactive Data File (embedded within the Inline XBRL, document)

SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

Date: August 6, 2026				ResMed Inc.
				(registrant)
				By:		/s/ Aaron Bloomer
				Name:		Aaron Bloomer
				Its:		Chief Financial Officer

Exhibit 99.1

For investors		For media
+1 858-221-3304		+1 619-510-1281
investorrelations@resmed.com		news@resmed.com

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026

• Q4 revenue increased by 9% to a record $1.5 billion; up 8% on a constant currency basis

• Q4 GAAP diluted earnings per share up 2% to $2.64; non-GAAP diluted earnings per share up 16% to $2.95

• Returned $1.0 billion to shareholders through share repurchases and dividends during FY2026, an increase of more than 70%

Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, August 6, 2026 – Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended June 30, 2026.

“We closed fiscal year 2026 with strong fourth quarter results, reflecting continued momentum of our global business, sustained demand for our market-leading products, and disciplined execution of our strategy,” said Resmed’s Chairman and CEO, Mick Farrell.

“Year-over-year, we delivered 9% reported revenue growth, 90 basis points of gross margin expansion, and a 16% increase in earnings per share. For full year 2026, our $1.6 billion in free cash flow enabled us to invest in innovation, strengthen our market leadership, and return more than $1 billion to our shareholders.”

“As we enter fiscal year 2027, we will leverage our global scale and enhance our digital capabilities to benefit our patients, providers, and customers. We will use our industry-leading portfolio to improve patient outcomes, reduce healthcare costs, and drive long-term profitable growth for our shareholders.”

Financial Highlights

• FY 2026 revenue increased by 10% to $5.7 billion; up 8% on a constant currency basis

• FY 2026 GAAP gross margin up 170 bps to 61.1%; non-GAAP gross margin up 240 bps to 62.4%

• FY 2026 GAAP operating margin up 70 bps to 33.4%, non-GAAP operating margin up 180 bps to 36.1%

• FY 2026 GAAP diluted earnings per share of $10.43; non-GAAP diluted earnings per share of $11.17, an increase of 17%

• FY 2026 operating cash flow of $1.8 billion; free cash flow of $1.6 billion

• Guiding to more than $1.85 billion in capital to be returned to shareholders through share repurchases and dividends during FY 2027; announced quarterly dividend increase of 10% to $0.66 per quarter

Other Business and Operational Highlights

• Announced agreement to sell MatrixCare business; transaction expected to close during the first quarter of Resmed’s fiscal year 2027.

• Completed acquisition of Noctrix Health, a medical device company selling FDA De Novo classified wearable therapeutics for Restless Leg Syndrome, or RLS.

• Partnered with ŌURA to expand access to sleep health education and pathways to care, helping more people sleep better and improve their overall health.

• Following other successful launches in APAC, EMEA and the Americas, launched AirSense 11 in Taiwan. Additionally, launched AirCurve 11 ST/ST-A in the U.S. and AirTouch F30i Comfort in Brazil and Chile.

RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026 Page 2 of 10

Financial Results and Operating Metrics

Unaudited; $ in millions, except for per share amounts

		Three Months Ended
		June 30, 2026				June 30, 2025				% Change				Constant Currency (A)
Revenue		$	1,464			$	1,348				9	%			8	%
Gross margin			58.8	%			60.8	%			(200) bps
Non-GAAP gross margin (B)			62.3	%			61.4	%			90 bps
Research and development expenses			106				86				22				19
Selling, general, and administrative expenses			296				267				11				8
Non-GAAP selling, general, and administrative expenses(B)			291				265				10				7
Income from operations			449				455				(1)
Operating margin			30.7	%			33.7	%			(300) bps
Non-GAAP income from operations (B)			515				476				8
Non-GAAP operating margin			35.2	%			35.3	%			(10) bps
Net income			383				380				1
Non-GAAP net income (B)			428				375				14
Diluted earnings per share		$	2.64			$	2.58				2
Non-GAAP diluted earnings per share (B)		$	2.95			$	2.55				16
Operating cash flow			455				539				(16)
Free cash flow(C)			404				508				(21)

		Twelve Months Ended
		June 30, 2026				June 30, 2025				% Change				Constant Currency (A)
Revenue		$	5,653			$	5,146				10	%			8	%
Gross margin			61.1	%			59.4	%			170 bps
Non-GAAP gross margin (B)			62.4	%			60.0	%			240 bps
Research and development expenses			378				331				14				12
Selling, general, and administrative expenses			1,120				993				13				10
Non-GAAP selling, general, and administrative expenses(B)			1,108				991				12				9
Income from operations			1,887				1,685				12
Operating margin			33.4	%			32.7	%			70 bps
Non-GAAP income from operations (B)			2,039				1,763				16
Non-GAAP operating margin			36.1	%			34.3	%			180 bps
Net income			1,523				1,401				9
Non-GAAP net income (B)			1,632				1,407				16
Diluted earnings per share		$	10.43			$	9.51				10
Non-GAAP diluted earnings per share (B)		$	11.17			$	9.55				17
Operating cash flow			1,806				1,752				3
Free cash flow(C)			1,650				1,662				(1	)

(A) In order to provide a framework for assessing how our underlying businesses performed, excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

(B) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

(C) Free cash flow is equal to operating cash flow less purchases of property, plant and equipment.

RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026 Page 3 of 10

Discussion of Fourth Quarter Results

All comparisons are to the prior year period unless otherwise noted

• Strong revenue growth: Revenue increased 9% (8% in constant currency) to approximately $1.5 billion, driven by strong demand across sleep devices, masks, accessories, and software solutions.

• Global momentum: Americas Sleep and Breathing Health revenue grew 8%, Rest of World Sleep and Breathing Health grew 10% in constant currency, and Residential Care Software revenue increased 2% in constant currency.

• Healthy profitability: GAAP gross margin of 58.8%. Non-GAAP gross margin increased 90 basis points to 62.3%, predominantly from productivity pipeline execution. The primary difference is our $42 million Astral field safety notification expenses.

• Robust earnings growth: GAAP income from operations of $449 million and GAAP diluted earnings per share of $2.64. Non-GAAP income from operations increased 8% and non-GAAP diluted earnings per share grew 16% to $2.95, predominantly attributable to strong sales growth and gross margin improvement.

• Strong cash generation: Operating cash flow totaled $455 million and free cash flow totaled $404 million, supporting $287 million returned to shareholders through dividends and share repurchases while maintaining investment in innovation and growth initiatives.

Dividend program

The Resmed board of directors today declared a quarterly cash dividend of $0.66 per share, representing an increase of 10% over our previous quarterly dividend. The dividend will have a record date of August 20, 2026, payable on September 24, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be August 19, 2026, for common stockholders and for CDI holders. Resmed has received a waiver from the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from August 19, 2026, through August 20, 2026, inclusive.

Webcast details

Resmed will discuss its fourth quarter fiscal year 2026 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on Resmed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q4 2026 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately three hours after the webcast by dialing +1 877-660-6853 (U.S.) or +1 201-612-7415 (outside U.S.) and entering the passcode 13761408. The telephone replay will be available until August 20, 2026.

About Resmed

Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.

RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026 Page 4 of 10

Safe harbor statement

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding Resmed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions of our business – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in Resmed’s periodic reports on file with the U.S. Securities & Exchange Commission. Resmed does not undertake to update its forward-looking statements.

– More –

RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026 Page 5 of 10

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(Unaudited; $ in thousands, except for per share amounts)

		Three Months Ended								Twelve Months Ended
		June 30, 2026				June 30, 2025				June 30, 2026				June 30, 2025
Net revenue		$	1,463,647			$	1,347,993			$	5,653,443			$	5,146,327
Cost of sales			552,245				520,068				2,128,040				2,060,753
Amortization of acquired intangibles (1)			8,301				9,367				31,779				32,116
Masks with magnets field safety notification expenses (1)			—				(1,512	)			—				(1,512	)
Astral field safety notification expenses (1)			41,885				—				41,885				—
Total cost of sales		$	602,431			$	527,923			$	2,201,704			$	2,091,357
Gross profit		$	861,216			$	820,070			$	3,451,739			$	3,054,970
Research and development			105,726				86,443				378,285				331,284
Selling, general, and administrative			290,655				265,125				1,108,042				991,019
Acquisition and portfolio review related expenses (1)			5,628				2,031				11,486				2,031
Total selling, general, and administrative			296,283				267,156				1,119,528				993,050
Amortization of acquired intangibles (1)			10,499				11,928				45,466				45,273
Restructuring expenses (1)			—				—				21,745				—
Total operating expenses		$	412,508			$	365,527			$	1,565,024			$	1,369,607
Income from operations		$	448,708			$	454,543			$	1,886,715			$	1,685,363
Other income (expenses), net:
Interest (expense) income, net		$	20,885			$	5,757			$	49,914			$	4,114
Gain (loss) attributable to equity method investments			2,232				1,269				6,955				3,644
Gain (loss) on equity investments			1,001				(2,533	)			(15,014	)			(10,299	)
Other, net			1,338				(983	)			(9,154	)			(5,256	)
Total other income (expenses), net			25,456				3,510				32,701				(7,797	)
Income before income taxes		$	474,164			$	458,053			$	1,919,416			$	1,677,566
Income taxes			90,732				78,348				396,123				276,843
Net income		$	383,432			$	379,705			$	1,523,293			$	1,400,723
Basic earnings per share		$	2.65			$	2.59			$	10.47			$	9.55
Diluted earnings per share		$	2.64			$	2.58			$	10.43			$	9.51
Non-GAAP diluted earnings per share (1)		$	2.95			$	2.55			$	11.17			$	9.55
Basic shares outstanding			144,706				146,472				145,523				146,716
Diluted shares outstanding			144,976				147,037				146,054				147,340

(1) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

– More –

RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026 Page 6 of 10

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(Unaudited; $ in thousands)

		June 30, 2026				June 30, 2025
Assets
Current assets:
Cash and cash equivalents		$	1,469,234			$	1,209,450
Accounts receivable, net			1,036,233				939,492
Inventories			945,805				927,711
Prepayments and other current assets			416,081				428,952
Assets held for sale		$	457,386			$	—
Total current assets		$	4,324,739			$	3,505,605
Non-current assets:
Property, plant, and equipment, net		$	581,829			$	550,790
Operating lease right-of-use assets			153,167				167,497
Goodwill and other intangibles, net			3,362,312				3,511,541
Deferred income taxes and other non-current assets			543,903				438,958
Total non-current assets		$	4,641,211			$	4,668,786
Total assets		$	8,965,950			$	8,174,391
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable		$	308,923			$	278,157
Accrued expenses			494,921				402,253
Operating lease liabilities, current			29,141				30,506
Deferred revenue			162,911				166,030
Income taxes payable			98,108				132,274
Short-term debt			259,950				9,900
Liabilities held for sale		$	41,156			$	—
Total current liabilities		$	1,395,110			$	1,019,120
Non-current liabilities:
Deferred revenue		$	170,951			$	156,803
Deferred income taxes			64,640				77,682
Operating lease liabilities, non-current			137,413				153,015
Other long-term liabilities			213,028				141,520
Long-term debt			399,415				658,392
Total non-current liabilities		$	985,447			$	1,187,412
Total liabilities		$	2,380,557			$	2,206,532
Stockholders’ equity
Common stock		$	764			$	761
Additional paid-in capital			2,190,614				2,033,599
Retained earnings			7,255,121				6,081,490
Treasury stock			(2,778,591	)			(2,073,292	)
Accumulated other comprehensive income			(82,515	)			(74,699	)
Total stockholders’ equity		$	6,585,393			$	5,967,859
Total liabilities and stockholders’ equity		$	8,965,950			$	8,174,391

– More –

RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026 Page 7 of 10

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited; $ in thousands)

		Three Months Ended								Twelve Months Ended
		June 30, 2026				June 30, 2025				June 30, 2026				June 30, 2025
Cash flows from operating activities:
Net income		$	383,432			$	379,705			$	1,523,293			$	1,400,723
Adjustment to reconcile net income to cash provided by operating activities:
Depreciation and amortization			44,778				63,628				201,342				198,473
Amortization of right-of-use assets			10,343				10,660				42,810				37,338
Stock-based compensation costs			27,458				24,751				104,348				91,661
(Gain) loss attributable to equity method investments, net of dividends received			2,340				(1,269	)			(2,382	)			(3,644	)
(Gain) loss on equity investments			(1,000	)			2,533				15,014				10,299
Gain on previously held equity investment			(4,353	)			—				(4,353	)			—
Changes in operating assets and liabilities:
Accounts receivable, net			(37,209	)			(5,215	)			(96,778	)			(76,684	)
Inventories, net			(33,866	)			(32,133	)			(9,920	)			(80,165	)
Prepaid expenses, net deferred income taxes and other current assets			12,150				47,017				(140,260	)			82,629
Accounts payable, accrued expenses, income taxes payable and other			50,558				49,089				172,715				90,958
Net cash provided by (used in) operating activities		$	454,631			$	538,766			$	1,805,829			$	1,751,588
Cash flows from investing activities:
Purchases of property, plant, and equipment			(51,127	)			(30,585	)			(156,285	)			(89,865	)
Patent registration and acquisition costs			(5,384	)			(3,193	)			(18,670	)			(10,777	)
Purchases of intangible assets			(739	)			—				(2,218	)			—
Business acquisitions, net of cash acquired			(325,319	)			(138,578	)			(350,724	)			(139,248	)
Purchases of investments			(2,000	)			(2,013	)			(28,536	)			(6,416	)
Proceeds from exits of investments			—				250				2,752				4,628
Proceeds (payments) on maturity of foreign currency contracts			918				40,406				8,482				41,633
Net cash provided by (used in) investing activities		$	(383,651	)		$	(133,713	)		$	(545,199	)		$	(200,045	)
Cash flows from financing activities:
Proceeds from issuance of common stock, net			29,314				30,156				74,503				74,439
Purchases of treasury stock			(200,000	)			(100,008	)			(700,037	)			(300,025	)
Acquisition of consolidated subsidiary			—				(10,855	)			—				(10,855	)
Taxes paid related to net share settlement of equity awards			(388	)			(590	)			(21,833	)			(18,077	)
Payments of business combination contingent consideration			—				—				—				(855	)
Repayment of borrowings			(5,000	)			(5,000	)			(10,000	)			(40,000	)
Dividends paid			(87,090	)			(77,590	)			(349,662	)			(310,880	)
Net cash provided by (used in) financing activities		$	(263,164	)		$	(163,887	)		$	(1,007,029	)		$	(606,253	)
Effect of exchange rate changes on cash		$	905			$	35,573			$	6,183			$	25,799
Net increase (decrease) in cash and cash equivalents			(191,279	)			276,739				259,784				971,089
Cash and cash equivalents at beginning of period			1,660,513				932,711				1,209,450				238,361
Cash and cash equivalents at end of period		$	1,469,234			$	1,209,450			$	1,469,234			$	1,209,450

– More –

RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026 Page 8 of 10

RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial Measures

(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles and field safety notification expenses and are reconciled below:

		Three Months Ended								Twelve Months Ended
		June 30, 2026				June 30, 2025				June 30, 2026				June 30, 2025
Revenue		$	1,463,647			$	1,347,993			$	5,653,443			$	5,146,327
GAAP cost of sales		$	602,431			$	527,923			$	2,201,704			$	2,091,357
Less: Amortization of acquired intangibles (A)			(8,301	)			(9,367	)			(31,779	)			(32,116	)
Less: Masks with magnets field safety notification expenses (A)			—				1,512				—				1,512
Less: Astral field safety notification expenses (A)			(41,885	)			—				(41,885	)			—
Non-GAAP cost of sales		$	552,245			$	520,068			$	2,128,040			$	2,060,753
GAAP gross profit		$	861,216			$	820,070			$	3,451,739			$	3,054,970
GAAP gross margin			58.8	%			60.8	%			61.1	%			59.4	%
Non-GAAP gross profit		$	911,402			$	827,925			$	3,525,403			$	3,085,574
Non-GAAP gross margin			62.3	%			61.4	%			62.4	%			60.0	%

The measures “non-GAAP selling, general, and administrative expenses” and “non-GAAP selling, general, and administrative expenses as a percentage of revenues” exclude acquisition and portfolio review related expenses and are reconciled below:

		Three Months Ended								Twelve Months Ended
		June 30, 2026				June 30, 2025				June 30, 2026				June 30, 2025
Revenue		$	1,463,647			$	1,347,993			$	5,653,443			$	5,146,327
GAAP selling, general, and administrative			296,283				267,156				1,119,528				993,050
Less: Acquisition and portfolio review related expenses (A)			(5,628	)			(2,031	)			(11,486	)			(2,031	)
Non-GAAP selling, general, and administrative			290,655				265,125				1,108,042				991,019
As a percentage of revenue:
GAAP selling, general, and administrative expenses			20.2	%			19.8	%			19.8	%			19.3	%
Non-GAAP selling, general, and administrative expenses			19.9	%			19.7	%			19.6	%			19.3	%

– More –

RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026 Page 9 of 10

RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial Measures

(Unaudited; $ in thousands, except for per share amounts)

The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:

		Three Months Ended								Twelve Months Ended
		June 30, 2026				June 30, 2025				June 30, 2026				June 30, 2025
GAAP income from operations		$	448,708			$	454,543			$	1,886,715			$	1,685,363
Amortization of acquired intangibles—cost of sales (A)			8,301				9,367				31,779				32,116
Amortization of acquired intangibles—operating expenses (A)			10,499				11,928				45,466				45,273
Restructuring (A)			—				—				21,745				—
Masks with magnets field safety notification expenses (A)			—				(1,512	)			—				(1,512	)
Astral field safety notification expenses (A)			41,885				—				41,885				—
Acquisition and portfolio review related expenses (A)			5,628				2,031				11,486				2,031
Non-GAAP income from operations		$	515,021			$	476,357			$	2,039,076			$	1,763,271

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

		Three Months Ended								Twelve Months Ended
		June 30, 2026				June 30, 2025				June 30, 2026				June 30, 2025
GAAP net income		$	383,432			$	379,705			$	1,523,293			$	1,400,723
Amortization of acquired intangibles—cost of sales (A)			8,301				9,367				31,779				32,116
Amortization of acquired intangibles—operating expenses (A)			10,499				11,928				45,466				45,273
Restructuring expenses (A)			—				—				21,745				—
Gain on previously held equity investment(A)			(4,353	)			—				(4,353	)			—
Masks with magnets field safety notification expenses (A)			—				(1,512	)			—				(1,512	)
Astral field safety notification expenses (A)			41,885				—				41,885				—
Acquisition and portfolio review related expenses (A)			5,628				2,031				11,486				2,031
Tax benefit from business cessation(A)			—				(21,430	)			—				(21,430	)
Income tax effect of interest and penalties on income tax refunds (A)			—				—				—				(29,976	)
Income tax effect on non-GAAP adjustments (A)			(17,059	)			(5,544	)			(39,453	)			(20,448	)
Non-GAAP net income (A)		$	428,333			$	374,545			$	1,631,848			$	1,406,777
GAAP diluted shares outstanding			144,976				147,037				146,054				147,340
GAAP diluted earnings per share		$	2.64			$	2.58			$	10.43			$	9.51
Non-GAAP diluted earnings per share (A)		$	2.95			$	2.55			$	11.17			$	9.55

(A) Resmed adjusts for the impact of the amortization of acquired intangibles, restructuring expenses, gains on previously held equity investments, field safety notification expenses, acquisition and portfolio review related expenses and associated tax effects, in addition to tax benefits from business cessation, and the tax effect of interest and penalties on tax refunds from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

Resmed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. Resmed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. Resmed believes this information provides investors better insight when evaluating Resmed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

– More –

RMD Fourth Quarter 2026 Earnings Press Release – August 6, 2026 Page 10 of 10

RESMED INC. AND SUBSIDIARIES

Revenue by Product and Region

(Unaudited; $ in millions, except for per share amounts)

		Three Months Ended
		June 30, 2026				(A)		June 30, 2025				(A)		% Change				Constant Currency (B)
Americas (C)
Devices		$	459					$	433						6	%
Masks and other			394						359						10
Total Americas (C)		$	853					$	792						8
Rest of World (C)
Devices		$	291					$	261						12	%			9	%
Masks and other			148						128						16				12
Total Rest of World (C)		$	439					$	389						13				10
Global revenue
Total Devices		$	750					$	694						8	%			7	%
Total Masks and other			542						487						11				10
Total Sleep and Breathing Health		$	1,292					$	1,181						9				8
Residential Care Software			172						167						3				2
Total		$	1,464					$	1,348						9				8

		Twelve Months Ended
		June 30, 2026				(A)		June 30, 2025				(A)		% Change				Constant Currency (B)
Americas (C)
Devices		$	1,768					$	1,654						7	%
Masks and other			1,513						1,343						13
Total Americas (C)		$	3,281					$	2,998						9
Rest of World (C)
Devices		$	1,124					$	1,011						11	%			6	%
Masks and other			572						497						15				9
Total Rest of World (C)		$	1,697					$	1,507						13				7
Global revenue
Total Devices		$	2,892					$	2,665						9	%			7	%
Total Masks and other			2,085						1,840						13				12
Total Sleep and Breathing Health		$	4,978					$	4,505						10				9
Residential Care Software			676						641						5				4
Total		$	5,653					$	5,146						10				8

(A) Totals and subtotals may not add due to rounding.

(B) In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

(C) Historically we have presented our geographical split of revenue as “U.S., Canada, and Latin America” and “Combined Europe, Asia, and other markets”. Effective this quarter, this presentation has been renamed to Americas (formerly U.S., Canada, and Latin America) and Rest of World (formerly Combined Europe, Asia, and other markets). The methodology for attributing revenue to these geographies remains unchanged. Revenue from prior periods is consistent and comparable to previous reporting.

– End –

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 289.3 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.5 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB